Cargando…
Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a progressive muscle disease involving complex skeletal muscle pathogenesis. The pathogenesis is triggered by sarcolemma instability due to the lack of dystrophin protein expression, leading to Ca(2+) influx, muscle fiber apoptosis, inflammation, muscle necrosis,...
Autores principales: | Ogundele, Michael, Zhang, Jesslyn S., Goswami, Mansi V., Barbieri, Marissa L., Dang, Utkarsh J., Novak, James S., Hoffman, Eric P., Nagaraju, Kanneboyina, Hathout, Yetrib |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401931/ https://www.ncbi.nlm.nih.gov/pubmed/34440571 http://dx.doi.org/10.3390/life11080827 |
Ejemplares similares
-
Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys
por: Dang, Utkarsh J, et al.
Publicado: (2020) -
Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020) -
Tandem Mass Tag-Based Serum Proteome Profiling for
Biomarker Discovery in Young Duchenne Muscular Dystrophy Boys
por: Alayi, Tchilabalo D., et al.
Publicado: (2020) -
Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2019) -
Clinical utility of serum biomarkers in Duchenne muscular dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2016)